Citations (77)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Laurent Laforest, Baishali M Ambegaonkar, Thierry Souchet, Vasilisa Sazonov & Eric Van Ganse. (2012) Mixed dyslipidemias in primary care patients in France. Vascular Health and Risk Management 8, pages 247-254.
Read now
Read now
Yun Lin, Shaymaa S Mousa, Nabil Elshourbagy & Shaker A Mousa. (2010) Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy. Vascular Health and Risk Management 6, pages 73-85.
Read now
Read now
Justin MS Lee & Robin P Choudhury. (2010) Atherosclerosis regression and high-density lipoproteins. Expert Review of Cardiovascular Therapy 8:9, pages 1325-1334.
Read now
Read now
J. Delgado Alves, E. Steinhagen-Thiessen, R. Darioli, U. Hostalek & A. Vogt. (2008) Influence of the timing of low-dose aspirin on tolerability of prolonged-release nicotinic acid in patients at elevated cardiovascular risk. Current Medical Research and Opinion 24:10, pages 2815-2820.
Read now
Read now
Jonathan Belsey, Simon de Lusignan, Tom Chan, Jeremy van Vlymen & Nigel Hague. (2008) Abnormal lipids in high-risk patients achieving cholesterol targets: a cross-sectional study of routinely collected UK general practice data. Current Medical Research and Opinion 24:9, pages 2551-2560.
Read now
Read now
José V. Lozano, Vicente Pallarés, Luis Cea-Calvo, José L. Llisterri, Cristina Fernández-Pérez, Juan C. Martí-Canales, Jose Aznar, Vicente Gil-Guillén & Josep Redón. (2008) Serum lipid profiles and their relationship to cardiovascular disease in the elderly: the PREV-ICTUS study. Current Medical Research and Opinion 24:3, pages 659-670.
Read now
Read now
Anja Vogt, Ursula Kassner, Ulrike Hostalek & Elisabeth Steinhagen-Thiessen. (2007) Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study. Vascular Health and Risk Management 3:4, pages 467-479.
Read now
Read now
M. Baccara-Dinet & E. Bruckert. (2007) Are physicians able to identify high-risk abdominally obese individuals? An analysis from the pan-European Survey of HDL‑cholesterol. Current Medical Research and Opinion 23:8, pages 2005-2008.
Read now
Read now
R. S. Birjmohun, J. J. P. Kastelein, D. Poldermans, E. S. G Stroes, U. Hostalek & G. Assmann. (2007) Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients. Current Medical Research and Opinion 23:7, pages 1707-1713.
Read now
Read now
S. Roze, D. Liens, A. Palmer, W. Berger, D. Tucker & C. Renaudin. (2006) A health economic model to determine the long-term costs and clinical outcomes of raising low HDL-cholesterol in the prevention of coronary heart disease. Current Medical Research and Opinion 22:12, pages 2549-2556.
Read now
Read now
Articles from other publishers (67)
Amirhossein Yadegar, Fatemeh Mohammadi, Soghra Rabizadeh, Alipasha Meysamie, Seyed Ali Nabipoorashrafi, Seyed Arsalan Seyedi, Alireza Esteghamati & Manouchehr Nakhjavani. (2023) Decreasing trend of blood lipid profile in type 2 diabetes: Not a promising change in HDL-C, a serial cross-sectional study. PLOS ONE 18:10, pages e0293410.
Crossref
Crossref
Wenjun Fan & Nathan D. Wong. 2023. Lipoproteins in Diabetes Mellitus. Lipoproteins in Diabetes Mellitus
891
913
.
Eliot A. Brinton & Vishnu Priya Pulipati. 2023. Lipoproteins in Diabetes Mellitus. Lipoproteins in Diabetes Mellitus
637
679
.
Ryutaro Nakamura, Mika Kurihara, Nobuhiro Ogawa, Akihiro Kitamura, Isamu Yamakawa, Shigeki Bamba, Mitsuru Sanada, Masaya Sasaki & Makoto Urushitani. (2022) Investigation of the prognostic predictive value of serum lipid profiles in amyotrophic lateral sclerosis: roles of sex and hypermetabolism. Scientific Reports 12:1.
Crossref
Crossref
Antonio Ruiz-García, Ezequiel Arranz-Martínez, María E. García-Fernández, Roberto Cabrera-Vélez, Rosa A. García-Pliego, Luis E. Morales-Cobos, Blanca Sanz-Pozo, Esther Gómez-Díaz, Enrique Rodríguez-de-Mingo, María R. Rico-Pérez, Alfonso Migueláñez-Valero, María P. Calderín-Morales, Eloína Sandín-de-Vega, María P. Hombrados-Gonzalo, Sonia Luna-Ramírez, María C. Sánchez-Ramos, Cristina Mora-Casado, María S. Moreno-Muñoz, Paloma González-Escobar, Lourdes Ruiz-Díaz, Nuria Caballero-Ramírez, María M. Zamora-Gómez, Nerea Iturmendi-Martínez, María S. Holgado-Catalán, Rebeca Álvarez-Benedicto, Pedro L. Sanchidriá-Fernández, Elena Benito-Alonso, Teresa Fernández-Vicente, Rosa M. Hernández-López, Norma A. Doria-Carlin & Manuel J. Frías-Vargas. (2021) Factores cardiometabólicos asociados y prevalencia de concentraciones bajas de colesterol HDL y de dislipidemia aterogénica. Estudio SIMETAP-DA. Clínica e Investigación en Arteriosclerosis 33:1, pages 19-29.
Crossref
Crossref
Antonio Ruiz-García, Ezequiel Arranz-Martínez, María E. García-Fernández, Roberto Cabrera-Vélez, Rosa A. García-Pliego, Luis E. Morales-Cobos, Blanca Sanz-Pozo, Esther Gómez-Díaz, Enrique Rodríguez-de-Mingo, María R. Rico-Pérez, Alfonso Migueláñez-Valero, María P. Calderín-Morales, Eloína Sandín-de-Vega, María P. Hombrados-Gonzalo, Sonia Luna-Ramírez, María C. Sánchez-Ramos, Cristina Mora-Casado, María S. Moreno-Muñoz, Paloma González-Escobar, Lourdes Ruiz-Díaz, Nuria Caballero-Ramírez, María M. Zamora-Gómez, Nerea Iturmendi-Martínez, María S. Holgado-Catalán, Rebeca Álvarez-Benedicto, Pedro L. Sanchidriá-Fernández, Elena Benito-Alonso, Teresa Fernández-Vicente, Rosa M. Hernández-López, Norma A. Doria-Carlin & Manuel J. Frías-Vargas. (2021) Related cardiometabolic factors and prevalence of low HDL-cholesterol levels and atherogenic dyslipidemia. SIMETAP-AD study. Clínica e Investigación en Arteriosclerosis (English Edition) 33:1, pages 19-29.
Crossref
Crossref
Pengfei Ge, Caixia Dong, Xiaolan Ren, Elisabete Weiderpass, Chouji Zhang, Haoqiang Fan, Jing Zhang, Yongrui Zhang & Jinen Xi. (2015) The High Prevalence of Low HDL-Cholesterol Levels and Dyslipidemia in Rural Populations in Northwestern China. PLOS ONE 10:12, pages e0144104.
Crossref
Crossref
Humaira Jamshed, Fateh Ali Tipoo Sultan, Romaina Iqbal & Anwar Hassan Gilani. (2015) Dietary Almonds Increase Serum HDL Cholesterol in Coronary Artery Disease Patients in a Randomized Controlled Trial. The Journal of Nutrition 145:10, pages 2287-2292.
Crossref
Crossref
Preethi Mani & Anand Rohatgi. (2015) Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?. Current Atherosclerosis Reports 17:8.
Crossref
Crossref
Jiantao Li, Yunfeng Han, Jing Jing, Shengxian Tu, Weiren Chen, Johan H. C. Reiber & Yundai Chen. (2015) Non-culprit coronary lesions in young patients have higher rates of atherosclerotic progression. The International Journal of Cardiovascular Imaging 31:5, pages 889-897.
Crossref
Crossref
Fabiana H. Rached, M. John Chapman & Anatol Kontush. (2015) HDL particle subpopulations: Focus on biological function. BioFactors 41:2, pages 67-77.
Crossref
Crossref
Peter P. Toth, Marcin Barylski, Dragana Nikolic, Manfredi Rizzo, Giuseppe Montalto & Maciej Banach. (2014) Should low high-density lipoprotein cholesterol (HDL-C) be treated?. Best Practice & Research Clinical Endocrinology & Metabolism 28:3, pages 353-368.
Crossref
Crossref
G. Sirimarco, J. Labreuche, E. Bruckert, L. B. Goldstein, K. M. Fox, P. M. Rothwell, P. Amarenco, M.-G. Bousser, A. Chamorro, I. Ford, K. Fox, M. Fisher, M. G. Hennerici, H. Mattle, P. M. Rothwell, F. Callahan, L. B. Goldstein, H. Sillesen, K. M. A. Welch & J. A. Zivin. (2014) Atherogenic Dyslipidemia and Residual Cardiovascular Risk in Statin-Treated Patients. Stroke 45:5, pages 1429-1436.
Crossref
Crossref
D. Devroey, R. P. Radermecker, B. J. Van der Schueren, B. Torbeyns & R. J. Jaken. (2013)
Prevalence of persistent lipid abnormalities in statin‐treated patients: Belgian results of the Dyslipidaemia International Study (
DYSIS
)
. International Journal of Clinical Practice 68:2, pages 180-187.
Crossref
Crossref
Nabil A. Elshourbagy, Harold V. Meyers & Sherin S. Abdel-Meguid. (2014) Cholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia. Medical Principles and Practice 23:2, pages 99-111.
Crossref
Crossref
Eliot A. Brinton. 2014. Lipoproteins in Diabetes Mellitus. Lipoproteins in Diabetes Mellitus
373
398
.
Soo Lim, Yae Min Park, Ichiro Sakuma & Kwang Kon Koh. (2013) How to control residual cardiovascular risk despite statin treatment: Focusing on HDL–cholesterol. International Journal of Cardiology 166:1, pages 8-14.
Crossref
Crossref
Anthony S. Wierzbicki, Rosemary E. Clarke, Adie Viljoen & Dimitri P. Mikhailidis. (2012) Triglycerides. Current Opinion in Cardiology 27:4, pages 398-404.
Crossref
Crossref
C. Lahoz, J.M. Mostaza, S. Tranche, R. Martin-Jadraque, M.T. Mantilla, I. López-Rodriguez, B. Monteiro, M.A. Sanchez-Zamorano & M. Taboada. (2012) Atherogenic dyslipidemia in patients with established coronary artery disease. Nutrition, Metabolism and Cardiovascular Diseases 22:2, pages 103-108.
Crossref
Crossref
Uchechukwu K. Sampson, Sergio Fazio & MacRae F. Linton. (2011) Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges. Current Atherosclerosis Reports 14:1, pages 1-10.
Crossref
Crossref
Anatol Kontush & M. John Chapman. 2011. High‐Density Lipoproteins. High‐Density Lipoproteins
113
160
.
E. Bruckert, J. Ferrières & M. Farnier. (2011) HDL-cholestérol et approche thérapeutique. Archives of Cardiovascular Diseases Supplements 3:4, pages 273-279.
Crossref
Crossref
J. Ferrières. (2011) HDL: facteur causal de l’athérosclérose ? Arguments épidémiologiques. Archives of Cardiovascular Diseases Supplements 3:4, pages 246-253.
Crossref
Crossref
Peter P. Toth. (2011) CETP Inhibition: Does the Future Look Promising?. Current Cardiology Reports 13:6, pages 559-565.
Crossref
Crossref
Rachel R. HuxleyFederica BarziTai Hing LamSebastien CzernichowXianghua FangTim WelbornJonathan ShawHirotsugu UeshimaPaul ZimmetSun Ha JeeJeetesh V. PatelIan CatersonVlado PerkovicMark Woodward. (2011) Isolated Low Levels of High-Density Lipoprotein Cholesterol Are Associated With an Increased Risk of Coronary Heart Disease. Circulation 124:19, pages 2056-2064.
Crossref
Crossref
Sun-Ja Choi, Sung-Hee Park & Hyun-Young Park. (2011) Increased Prevalence of low High-density Lipoprotein Cholesterol (HDL-C) Levels in Korean Adults: Analysis of the Three Korean National Health and Nutrition Examination Surveys (KNHANES 1998–2005). Osong Public Health and Research Perspectives 2:2, pages 94-103.
Crossref
Crossref
Alparslan Turan, Maria L. Mendoza, Shipra Gupta, Jing You, Alexandru Gottlieb, Weihan Chu, Leif Saager & Daniel I. Sessler. (2011) Consequences of Succinylcholine Administration to Patients Using Statins. Anesthesiology 115:1, pages 28-35.
Crossref
Crossref
Ana Jover, Emili Corbella, Anna Muñoz, Jesús Millán, Xavier Pintó, Alipio Mangas, Manuel Zúñiga, Juan Pedro-Botet & Antonio Hernández-Mijares. (2011) Prevalencia del síndrome metabólico y de sus componentes en pacientes con síndrome coronario agudo. Revista Española de Cardiología 64:7, pages 579-586.
Crossref
Crossref
Ana Jover, Emili Corbella, Anna Muñoz, Jesús Millán, Xavier Pintó, Alipio Mangas, Manuel Zúñiga, Juan Pedro-Botet & Antonio Hernández-Mijares. (2011) Prevalence of Metabolic Syndrome and its Components in Patients With Acute Coronary Syndrome. Revista Española de Cardiología (English Edition) 64:7, pages 579-586.
Crossref
Crossref
Billie Pettersson, Baishali Ambegaonkar, Vasilisa Sazonov, Mats Martinell, Jan Stålhammar & Per Wändell. (2010) Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA). BMC Public Health 10:1.
Crossref
Crossref
Anselm K. Gitt, Claus Jünger, Wenefrieda Smolka & Kurt Bestehorn. (2010) Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany. Clinical Research in Cardiology 99:11, pages 723-733.
Crossref
Crossref
Peter P. Toth & Michael H. Davidson. (2010) High-density lipoproteins: Marker of cardiovascular risk and therapeutic target. Journal of Clinical Lipidology 4:5, pages 359-364.
Crossref
Crossref
E. Bruckert, M. Farnier & J. Ferrières. (2010) HDL-cholestérol et risque cardiovasculaire : au-delà du LDL !. Médecine des Maladies Métaboliques 4:4, pages 379-388.
Crossref
Crossref
Peter P. Toth. (2010) Fibrate Therapy in the Management of Diabetic Dyslipidemia: There is No ACCORD to be Found. Current Atherosclerosis Reports 12:5, pages 331-335.
Crossref
Crossref
Anthony S Wierzbicki. (2010) Fibrates: no ACCORD on their use in the treatment of dyslipidaemia. Current Opinion in Lipidology 21:4, pages 352-358.
Crossref
Crossref
M. John Chapman, Jan S. Redfern, Mark E. McGovern & Philippe Giral. (2010) Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk. Pharmacology & Therapeutics 126:3, pages 314-345.
Crossref
Crossref
Eric Bruckert, Julien Labreuche & Pierre Amarenco. (2010) Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 210:2, pages 353-361.
Crossref
Crossref
Jean Ferrières, Emilie Bérard, Oliviu Crisan & Vanina Bongard. (2010) Residual dyslipidaemia after statin treatment in France: Prevalence and risk distribution. Archives of Cardiovascular Diseases 103:5, pages 302-309.
Crossref
Crossref
K. A.A. Fox, J.-P. Despres, A.-J. Richard, S. Brette & J. E. Deanfield. (2009) Does abdominal obesity have a similar impact on cardiovascular disease and diabetes? A study of 91 246 ambulant patients in 27 European Countries. European Heart Journal 30:24, pages 3055-3063.
Crossref
Crossref
Derek J Hausenloy & Derek M Yellon. (2009) Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels. Current Opinion in Cardiology 24:5, pages 473-482.
Crossref
Crossref
Antonio Coca, Luis Cea-Calvo, José V. Lozano, Verónica Inaraja, Cristina Fernández-Pérez, Jorge Navarro, Álvaro Bonet & Josep Redón. (2009) High-Density Lipoprotein Cholesterol and Cardiovascular Disease in Spanish Hypertensive Women. The RIMHA Study. Revista Española de Cardiología (English Edition) 62:9, pages 1022-1031.
Crossref
Crossref
Antonio Coca, Luis Cea-Calvo, José V. Lozano, Verónica Inaraja, Cristina Fernández-Pérez, Jorge Navarro, Álvaro Bonet & Josep Redón. (2009) Colesterol HDL y enfermedad cardiovascular en mujeres hipertensas de España. Estudio RIMHA. Revista Española de Cardiología 62:9, pages 1022-1031.
Crossref
Crossref
D. D. Waters, C. Brotons, C.-W. Chiang, J. Ferrieres, J. Foody, J. W. Jukema, R. D. Santos, J. Verdejo, M. Messig, R. McPherson, K.-B. Seung & L. Tarasenko. (2009) Lipid Treatment Assessment Project 2: A Multinational Survey to Evaluate the Proportion of Patients Achieving Low-Density Lipoprotein Cholesterol Goals. Circulation 120:1, pages 28-34.
Crossref
Crossref
Anthony S Wierzbicki. (2009) Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. Current Opinion in Cardiology 24:4, pages 372-379.
Crossref
Crossref
Axel Linke, Melanie Sonnabend, Mathias Fasshauer, Robert Höllriegel, Gerhard Schuler, Josef Niebauer, Michael Stumvoll & Matthias Blüher. (2009) Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis 205:1, pages 207-213.
Crossref
Crossref
P. P. Toth. (2009) Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice perspective. International Journal of Clinical Practice 63:6, pages 903-911.
Crossref
Crossref
L. Cea-Calvo, J. V. Lozano, C. Fernández-Pérez, J. L. Llisterri, J. C. Martí-Canales, J. Aznar, V. Gil-Guillén & J. Redón. (2009) Prevalence of low HDL cholesterol, and relationship between serum HDL and cardiovascular disease in elderly Spanish population: the PREV-ICTUS study. International Journal of Clinical Practice 63:1, pages 71-81.
Crossref
Crossref
Laurent Laforest, Thierry Souchet, Philippe Moulin, Cécile Ritleng, Gaëlle Desamericq, Philippe Le Jeunne, Marie-Sophie Schwalm & Eric Van Ganse. (2009) Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs. Archives of Cardiovascular Diseases 102:1, pages 43-50.
Crossref
Crossref
Stavroulla Xenophontos, Marilena Hadjivassiliou, Alexandros Karagrigoriou, Nafsika Demetriou, George Miltiadous, Ioannis Marcou, Moses Elisaf, Dimitri P Mikhailidis & Marios A Cariolou. (2008) Low HDL Cholesterol, Smoking and IL-13 R130Q Polymorphism are Associated with Myocardial Infarction in Greek Cypriot Males. A Pilot Study. The Open Cardiovascular Medicine Journal 2:1, pages 52-59.
Crossref
Crossref
Emil M. deGoma, Nicholas J. Leeper & Paul A. Heidenreich. (2008) Clinical Significance of High-Density Lipoprotein Cholesterol in Patients With Low Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology 51:1, pages 49-55.
Crossref
Crossref
S. Roze, J. Ferrières, E. Bruckert, E. Van Ganse, M. J. Chapman, D. Liens & C. Renaudin. (2007) Cost-effectiveness of raising HDL cholesterol by adding prolonged-release nicotinic acid to statin therapy in the secondary prevention setting: a French perspective. International Journal of Clinical Practice 61:11, pages 1805-1811.
Crossref
Crossref
A. Vogt, U. Kassner, U. Hostalek & E. Steinhagen-Thiessen. (2007) Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan®). International Journal of Clinical Practice 61:11, pages 1914-1921.
Crossref
Crossref
E. Bruckert & B. Hansel. (2007) HDL-c is a powerful lipid predictor of cardiovascular diseases. International Journal of Clinical Practice 61:11, pages 1905-1913.
Crossref
Crossref
Eric Van Ganse, Laurent Laforest, Thomas Burke, Hemant Phatak & Thierry Souchet. (2007) Mixed Dyslipidemia Among Patients Using Lipid-Lowering Therapy in French General Practice: An Observational Study. Clinical Therapeutics 29:8, pages 1671-1681.
Crossref
Crossref
. 2007. Comprehensive Management of High Risk Cardiovascular Patients. Comprehensive Management of High Risk Cardiovascular Patients
295
339
.
Eberhard WindlerMark SchöffauerBirgit-Christiane Zyriax. (2016) The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease. Diabetes and Vascular Disease Research 4:2, pages 136-142.
Crossref
Crossref
E. Bruckert, M. Baccara-Dinet & E. Eschwege. (2007) Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan-European survey. Diabetic Medicine 24:4, pages 388-391.
Crossref
Crossref
Barbara J. Meyer, Tone Hammervold, Arild Chr. Rustan & Peter R. C. Howe. (2007) Dose-Dependent Effects of Docosahexaenoic Acid Supplementation on Blood Lipids in Statin-Treated Hyperlipidaemic Subjects. Lipids 42:2, pages 109-115.
Crossref
Crossref
Peter P Toth & Antonio M GottoJrJr. 2006. Comprehensive Management of High Risk Cardiovascular Patients. Comprehensive Management of High Risk Cardiovascular Patients
295
340
.
M. FARNIER, P. GARNIER, C. YAU, S. DEJAGER & MP VERPILLEUX. (2006) Prevalence of low HDL-cholesterol in patients with cardiovascular risk factors: the ECHOS (Etude du Cholesterol HDL en Observationnel) French Survey. International Journal of Clinical Practice 60:10, pages 1166-1171.
Crossref
Crossref
Anthony S. Wierzbicki. (2006) Low HDL-cholesterol: common and under-treated, but which drug to use?. International Journal of Clinical Practice 60:10, pages 1149-1153.
Crossref
Crossref
Allen J. Taylor. (2006) Evidence to support aggressive management of HDL-cholesterol: implications of recent trials. European Heart Journal Supplements 8:suppl_F, pages F74-F80.
Crossref
Crossref
M. John Chapman. (2006) How does nicotinic acid modify the lipid profile?. European Heart Journal Supplements 8:suppl_F, pages F54-F59.
Crossref
Crossref
Heinz Drexel. (2006) Reducing risk by raising HDL-cholesterol: the evidence. European Heart Journal Supplements 8:suppl_F, pages F23-F29.
Crossref
Crossref
Eric Bruckert. (2006) Epidemiology of low HDL-cholesterol: results of studies and surveys. European Heart Journal Supplements 8:suppl_F, pages F17-F22.
Crossref
Crossref
Terje R. Pedersen. (2006) The gap between theory and practice: what do the trials tell us?. European Heart Journal Supplements 8:suppl_F, pages F10-F16.
Crossref
Crossref
Terje R Pedersen, Gerd Assmann, Jean-Pierre Bassand, M John Chapman, Raimund Erbel & Cesare Sirtori. (2016) Reducing residual cardiovascular risk: the relevance of raising high-density lipoprotein cholesterol in patients on cholesterol-lowering treatment. Diabetes and Vascular Disease Research 3:2_suppl, pages S1-S12.
Crossref
Crossref